Results 41 to 50 of about 5,687 (195)
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
Journal of Hematology & Oncology, 2022 Background Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension.
Sunnia T. Chen +17 more
doaj +1 more source
Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia [PDF]
, 2016 MicroRNAs (miRNAs) are small regulatory molecules that negatively regulate gene expression by base-pairing with their target mRNAs. miRNAs have contribute significantly to cancer biology and recent studies have demonstrated the oncogenic or tumor ...
Ashrafi Dehkordi, Korosh. +9 more
core +1 more source
The role of acalabrutinib in adults with chronic lymphocytic leukemia
Therapeutic Advances in Hematology, 2021 The treatment landscape of chronic lymphocytic leukemia (CLL) has significantly changed in the past decade. This paradigm shift is due to the introduction of novel agents to the field. The two major classes of drugs that have contributed to this dramatic
Bita Fakhri, Charalambos Andreadis
doaj +1 more source
Pharmaceuticals, 2021 Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median duration of survival of approximately 14 months after diagnosis. High resistance to chemotherapy remains a major problem.
Yu-Kai Su +8 more
doaj +1 more source
Cancer Management and Research, 2020 Krista Isaac,1 Anthony R Mato2 1Division of Hematology and Oncology, University of Virginia Health System, Charlottesville, VA, USA; 2Chronic Lymphocytic Leukemia Program, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence: Krista ...
Isaac K, Mato AR
doaj
Frontiers in Oncology, 2021 The BTK inhibitors ibrutinib and acalabrutinib are FDA-approved drugs for the treatment of B cell malignances. Both drugs have demonstrated clinical efficacy and safety profiles superior to chemoimmunotherapy regimens in patients with chronic lymphocytic
Sining Zhu +9 more
doaj +1 more source
How to perform aggregometry and lumi-aggregometry in mouse platelets [PDF]
, 2018 Light transmission aggregometry (LTA) and lumi-aggregometry are the gold standard platelet assays both clinically and for basic research. The availability of different strains of genetically modified mice, and mouse models of human disease means that ...
Craig E. Hughes +4 more
core +1 more source
Bruton’s tyrosine kinase inhibitors impair FcγRIIa-mediated platelet responses to bacteria in chronic lymphocytic leukaemia [PDF]
, 2021 Ibrutinib is highly effective in the treatment of chronic lymphocytic leukaemia (CLL), disrupting B cell receptor signalling through the inhibition of Bruton’s tyrosine kinase (Btk).
Naylor-Adamson, Leigh
core +3 more sources
Mechanisms of tumor cell resistance to the current targeted-therapy agents [PDF]
, 2016 Resistance to chemotherapy agents is a major challenge infront of cancer patient treatment and researchers. It is known that several factors, such as multidrug resistance proteins and ATP-binding cassette families, are cell membrane transporters that
Hojjat Farsangi, Mohammad +4 more
core +2 more sources
Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option [PDF]
, 2023 Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL).
Allsup, David +3 more
core +1 more source